



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/696,671
Applicant : Ivarie et al
Filed : October 28, 2003
Title : Transgenic Avians That Lay Eggs Containing Exogenous Proteins (amended)

TC/A.U. : 1633
Examiner : Kaushal, Sumesh

Docket No. : AVI-000CON

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on or before:

Date August 13, 2007

Signature [Handwritten Signature]

Name Kyle Yesland

Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION OF DR. ROBERT D. IVARIE PURSUANT TO 37 CFR 1.132

(IVARIE DECLARATION)

Sir:

I, Dr. Robert D. Ivarie, hereby declare as follows:

1. I currently hold the position of Professor and Head of Genetics, University of Georgia. My professional experience and educational background are detailed in my attached curriculum vitae (IVARIE CURRICULUM VITAE).

2. As a co-inventor, I have personal knowledge of the invention disclosed and claimed in the above-referenced patent application (hereinafter the "Application").

3. I understand that the Patent Examiner in the subject case has rejected certain claims based on the premise that making germ-line transgenic avians which produce exogenous protein in the oviduct is unpredictable and not routine and that the experimentation required to do so is undue.

4. The Application as originally filed was sufficient at the time of filing to enable a practitioner of ordinary skill in the art to produce a wide variety of exogenous proteins in the oviduct of germline transgenic avians on a routine basis. In fact, the methods disclosed in the Application have proven to be robust and reliable enabling us to successfully make germline transgenic birds which lay eggs containing a number of proteins specifically named in the Application (for example, at page 31 of the Application) including: β -lactamase, granulocyte colony stimulating factor (G-CSF), erythropoietin (EPO) and interferon, i.e., interferon alpha 2 (IFN α 2). Furthermore, by following the disclosure of the Application, a practitioner of ordinary skill in the art would be able to make lines of germline transgenic avians that lay eggs containing many different proteins in addition to those proteins that have been produced thus far and in addition to those proteins disclosed in the Application.

5. Germline transgenic chickens that produce beta lactamase (BL) in their oviduct were made in accordance with the Application. The data for the production of BL germline transgenic birds is as follows:

Production of G0 chimeric germline transgenic NLB-CMV-BL chickens was described in Examples 1 to 3 of the Application. G1 germline transgenic birds that produce BL in the oviduct were produced from the chimeric germline transgenic G0 male bird having the highest level of transgene in the sperm using standard breeding methodologies apparent to practitioners of ordinary skill in the art, i.e., the G0 roosters containing transgene in their sperm were crossed with non-transgenic chickens. Out of a total of 1026 G1 offspring tested by PCR analysis of genomic DNA, one rooster and two hens tested positive for the NLB-CMV-BL transgene. Eggs laid by the G1 germline transgenic females and their descendents contained between about 0.5 μ g/ml and about 1.6 μ g/ml of

BL, as determined by ELISA.

6. The methods used for making germline transgenic avians that produce G-CSF, EPO and interferon are disclosed in the Application. That is, the NLB-CMV-BL vector of Example 1 in the Application was altered to replace the BL coding sequence of the vector with the coding sequences for G-CSF, EPO and IFN α 2. Germline transgenic birds were obtained using these modified NLB-CMV vectors in accordance with methods disclosed in the Application. These results are discussed in the following paragraphs.

7. Germline transgenic chickens that produce IFN α 2 in their oviduct were made in accordance with the Application. The IFN α 2 coding sequence was optimized for chicken codon usage, though such codon modification is not required to obtain useful yield of exogenous protein from the egg white as can be seen in the production of other proteins described herein. The description for the production of IFN α 2 germline transgenic chickens is as follows:

The BL coding sequence of NLB-CMV-BL was replaced with the IFN α 2 coding sequence optimized for chicken codon usage, producing NLB-CMV-IFN α 2. NLB-CMV-IFN α 2 transduction particles were produced essentially as described in Example 2 of the Application. 300 White Leghorn chicken eggs were windowed and injected with the transduction particles essentially as described in Example 3 of the Application. Three chimeric germline transgenic G0 roosters with the highest NLB-CMV-IFN α 2 transgene level in their sperm were bred to non-transgenic females by artificial insemination to produce G1 birds. The 1,597th G1 offspring tested by PCR analysis of genomic DNA was a germline transgenic male carrying the NLB-CMV-IFN α 2 transgene. The male G1 offspring was bred to non-transgenic female chickens by artificial insemination to produce G2 offspring. Egg white from eggs laid by G2 germline transgenic females and their descendents contained on average about 2.7 μ g/ml of IFN α 2, as determined by ELISA. Purified IFN α 2 obtained from eggs of the G2 birds and their descendents has entered clinical trials for FDA regulatory approval. Purification of exogenous proteins such as IFN α 2 from eggs laid by transgenic birds can readily be accomplished by a practitioner of ordinary skill in the art using standard protein purification methodologies.

8. Germline transgenic chickens that produce G-CSF in their oviduct were made in accordance with the Application. The G-CSF coding sequence used was the human G-CSF nucleotide coding sequence. The description for the production of G-CSF germline transgenic chickens is as follows:

The IFN α 2 coding sequence of NLB-CMV-IFN α 2 was replaced with the human G-CSF coding sequence producing NLB-CMV-G-CSF. NLB-CMV-G-CSF transduction particles were produced essentially as described in Example 2 of the Application. 274 White Leghorn chicken eggs were windowed and injected with the transduction particles essentially as described in Example 3 of the Application. 41 of the eggs hatched. Two chimeric germline transgenic G0 roosters positive for the NLB-CMV-G-CSF transgene were bred to non-transgenic females by artificial insemination producing 4353 offspring, 14 of which were identified as germline transgenic G1's carrying the NLB-CMV-G-CSF transgene. Egg white of eggs laid by the G1 germline transgenic females and their descendents contained an average of about 3 μ g/ml of G-CSF, as determined by ELISA. Purified G-CSF obtained from eggs of these G1 birds and their descendents has entered clinical trials for FDA regulatory approval. Purification of exogenous proteins such as G-CSF from eggs laid by transgenic birds can readily be accomplished by a practitioner of ordinary skill in the art using standard protein purification methodologies.

9. Germline transgenic chickens that produce EPO in their oviduct were made in accordance with the Application. The EPO coding sequence used was the human EPO nucleotide coding sequence. The description for the production of EPO germline transgenic chickens is as follows:

The IFN α 2 coding sequence of NLB-CMV-IFN α 2 was replaced with the human EPO coding sequence producing NLB-CMV-EPO. NLB-CMV-EPO transduction particles were produced essentially as described in Example 2 of the Application. 1234 White Leghorn chicken eggs were windowed and injected with the transduction particles essentially as described in Example 3 of the Application. 334 of the eggs hatched. Seven of the hatched G0 roosters tested positive for the NLB-CMV-EPO transgene.

Three chimeric germline transgenic roosters that tested positive for the NLB-CMV-EPO transgene were bred to non-transgenic females by artificial insemination to produce 1190 offspring, 14 of which were transgene positive germline transgenic G1's. Egg white of eggs laid by the G1 germline transgenic females or their descendents contained about 0.4 to 1.9 µg/ml of EPO, as determined by ELISA. Purification of exogenous proteins such as EPO from eggs laid by transgenic birds can readily be accomplished by a practitioner of ordinary skill in the art using standard protein purification methodologies and, in fact, transgenic chicken derived EPO has been purified from eggs for use in *in vivo* and *in vitro* erythropoietin activity studies.

10. From the proceeding paragraphs it can be seen that production of transgenic birds that produce exogenous proteins in the oviduct is predictable and routine when following the teachings of the Application. As is expected a number of transgenic birds typically need to be screened in order to identify the transgenic G1 offspring (first generation of fully transgenic germline birds) obtained from the germline chimeras. However, such screening and identification can be accomplished routinely and with predictability by skilled technicians in the field of poultry science and molecular biology. In addition, identifying lines of G1 birds which lay eggs containing useful quantities of the transgene encoded exogenous protein has been predictable and routine using vectors of the invention. For example, use of the non-tissue specific CMV promoter to express the exogenous protein in the avian oviduct has been routine and has not required undue experimentation. In addition, random integration of the NLB vector into the avian genome has not made practicing the invention unpredictable and has not imposed undue experimentation in order to practice the invention.

11. Approximately 50% of offspring produced by crossing non-transgenic birds with the G1 germline transgenic avians produced in accordance with the Application (and having a confirmed single transgene copy in their genome) were transgene positive. This inheritance pattern is what is expected based upon Mendelian inheritance, thus providing further confirmation of germline transmission originating from the germline chimeric birds. Furthermore, approximately half of all subsequent

offspring (G3, G4, G5, ect) obtained from the germline transgenic avian lines produced in accordance with the Application have been fully germline transgenic, as would be expected in stable germline transmission of a hemizygous allele.

12. In addition to the production of germline transgenic chickens, I believe that the vectors and methods described in the Application can be used to produce germline transgenic avians other than chickens. In particular, the infectivity of ALV is not limited to chickens. In support of this, provided below is data showing production of transgenic quails that were produced using the NLB-CMV-G-CSF retroviral vector of paragraph 8 above and methods described in the Application.

13. Fertilized quail eggs were windowed and injected with NLB-CMV-G-CSF transduction particles essentially as described in Example 3 of the Application and approximately 24% of the hatched G0 hens were positive for the NLB-CMV-G-CSF transgene. Eggs of the G0 transgenic quail hens contained between about 25 pg and about 160 pg of G-CSF as determined by ELISA of the egg white from eggs laid by the birds. A low yield of exogenous protein in the egg white is not unexpected in eggs of G0 avians since the birds will be chimeric for the transgene (i.e., only a small percentage of the cells in the G0 birds will be transgene positive).

14. The reason for producing these transgenic quail was for purposes related specifically to quantification of promoter activity, which can be accomplished in G0 chimeric birds. The reason to use quail for this purpose is the rapid maturation rate (time from hatch to egg laying) of quail compared to chickens, 6 weeks for quail opposed to 20-22 weeks for chickens. The transgenic quail were not made with the goal of producing a germline transgenic flock to produce exogenous proteins because the volume of egg white contained in a quail egg is quite small compared to that of a chicken. Therefore, the laborious task of screening for germline transgenic quail was not undertaken. However, I believe with a high level of certainty that G1 germline transgenic quail which produce exogenous protein in the oviduct could be obtained from the transgenic G0 quails that were produced. In addition, I believe germline transgenic

avians other than chicken and quail which produce exogenous protein in the oviduct can be produced in accordance with the invention as disclosed in the Application.

15. I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both under section 1001 of title 18 of the United States Code and that such willful false statements may jeopardize the validity of the Application or any patent issuing thereon.

Signed Robert D. Ivarie
Robert D. Ivarie, Ph.D.

Dated 8/10/07



IVARIE CURRICULUM VITAE

NAME: Robert Ivarie
ADDRESS: Department of Genetics
Life Sciences Building
University of Georgia
Athens, Georgia 30602-7223

EDUCATION Ph.D., September, 1972, University of Colorado, Department of Molecular, Cellular & Developmental Biology, Boulder, Colorado, in Biology
A.B., June, 1967, Stanford University, Stanford, California, in Biological Sciences with Honors and Distinction.

PROFESSIONAL AND RESEARCH EXPERIENCE

7/04 to present Head, Department of Genetics, University of Georgia, Athens
11-96 to present Adjunct Professor of Animal and Dairy Science, University of Georgia, Athens
7-96 to present Chief Scientific Officer (through 1999), Chairman of the Scientific Advisory Board, & Scientific Co-founder, *ex officio* member, Board of Directors, AviGenics, inc., Athens, Georgia

9-93 to present Professor, Department of Genetics, University of Georgia, Athens
9-86 to 8-93 Associate Professor, Department of Genetics, University of Georgia, Athens
3-80 to 8-86 Assistant Professor, Department of Genetics, University of Georgia, Athens
9-77 to 2-80 Adjunct Assistant Professor, Endocrine Res. Div, Metabolic Research Unit, Dept of Medicine, University of California, San Francisco
1-77 to 9-77 Postgraduate Res, Assoc., Metabolic Res. Unit, Univ. of Calif., San Francisco;
Sponsor: John D. Baxter
Subject of research: Two-dimensional analysis of thyroid and steroid hormone responses in rat pituitary tumor cells; characterization of pituitary cell lines defective in *prolactin* gene expression.

9-72 to 1-77 Postdoctoral Fellow, Department of Biochemistry and Biophysics, University of California, San Francisco, Lecturer, Biochemistry 1976
Sponsor: Gordon M. Tomkins
Subject of research: Steroid-mediated regulation of enzymes and specific proteins in rat hepatoma cells.

9-67 to 9-72 Graduate Student, University of Colorado, Department of Molecular, Cellular and Developmental Biology, Boulder, CO .
Sponsor: Jacques J. Pene
Subject of research: Association of bacterial and viral deoxyribonucleic acid with the cell membrane.

9-66 to 9-67 Undergraduate Student, Stanford University, Department of Biological Sciences, Stanford, CA
Sponsor: Norman K. Wessells
Subject of research: Developmental aspects of the cell cycle of the unicellular alga, *Acetabularia*.

PAST FUNDING

"Mutations Affecting Gene Expression in Tumor Cells," National Science Foundation, \$50,928, 9/77-3/80.
"Mutations Affecting Gene Expression in Tumor Cells," National Cancer Institute, \$147,000, 5/78-5/82.
"Induction of DNA Methylation in vivo by Chemical Carcinogens," University of Georgia Faculty Research Grant, \$4,600, 7/82-6/83.
"Purification of a Plant DNA Methylase," University of Georgia Faculty Research Grant, \$4,000, 2/84-1/85.

Multiuser Instrumentation Grant for DNA Synthesizer and Protein Sequenator, National Science Foundation, \$134,000 (Co-PI with six UGA faculty; R. Meagher, PI).

Biomedical Research Support Grant Program: NIH, \$7,000, 1/87-6/87.

Biological Sequence Computation Facility, NSF Instrumentation grant, \$190,000 for computer equipment with \$200,000 matching funds from The University of Georgia Research Foundation (Co-PI with 10 faculty; J. Arnold and R. Meagher, PI's).

"Inactivation of Gene Expression by DNA Alkylating Agents," NCI, \$468,000 (TDC), 7/83-6/91.

"Embryonic Expression of myogenic factor genes in muscles of genetically large and small Japanese quail, University of Georgia Research Foundation, Inc. Biotechnology Program, \$72,000, 7/91-6/93.

"Molecular Structure and Function of Bovine *Myf-5*" Eli Lilly Company, \$544,000 (TDC), 11/88 to 6-93.

"Cellular and molecular determinants of differential muscle growth and differentiation in Japanese quail lines divergently selected for body weight," University of Georgia Research Foundation, \$86,500 (TDC when fringe benefits included), 7/95-6/97.

"Promoter-Less Minigene Insertion Technology in Avian Transgenesis," Faculty Research Commercialization Program, Advanced Technology Development Center of the State of Georgia, \$50,000, 7/96-6-97.

"Modification of the avian genome via homologous recombination, University of Georgia Research Foundation Biotechnology Program, \$73,000, 7/96-6/98.

Equipment Grant, Georgia Research Alliance, \$250,000, 1998. Technology Development Program of the Georgia Research Alliance, Phases I-III, \$150,000, 7/96- 6/99.

Applied Genetic Technology Resource (AGTEC), University of Georgia, 1997-99, Avian Transgenesis Resource, Georgia Research Alliance: (1) \$175,000, renovation, 4th floor of the new Animal Science Building, (2) \$1,125,000, facilities planning funds, (3) \$1,015,000 equipment funds; and (4) \$8,000,000 for research buildings. (Funds in support of plant and animal transgenic groups overseen by a 7 member executive committee of which I am a member).

Applied Genetic Technology Resource (AGTEC), University of Georgia, 1997-00, Georgia Research Alliance, \$1,500,000 Avian Transgenic Facility.

"Rational design of ribozymes for gene inactivation based on intracellular targeting," University of Georgia Research Foundation Biotechnology Award, \$72,562, Co-PI with Michael Terns, 7/99-6/01.

"Modification of the avian genome via transgenesis," AviGenics, Inc. \$1.35M , 4/96-6/03.

"Genes for Georgia," National Science Foundation, Partnerships for Innovation program, PI Karen Holbrook, CoPIs myself and Andy Paterson, \$600,000, 3/15/02-3/14/05

PROFESSIONAL SOCIETIES

American Association for the Advancement of Science

ACADEMIC HONORS

Undergraduate:

University Scholarship (9/62-6/63)
Nathaniel Green Guiberson, Jr. Scholarship (9/65-9/66)
Mary Yost Honors Scholarship (9/66-9/67)
Graduated with Distinction and with Honors in Biology (1967)

Postgraduate:

Graduate National Science Foundation Trainee (9/67-9/68)
National Science Education Act Fellow (9/68-9/71)
Leukemia Society of America, Postdoctoral Fellow (9/72-8/74)
National Institute of Health, Postdoctoral Fellow (6/75-5/76)

Faculty:

Best Cover, *Biotechniques* 1992
Fellow, American Association for the Advancement of Science (2005-)
University of Georgia Inventor's Award, 2007

SERVICE TO GRANTING AGENCIES/CONSULTATION/ORGANIZING SYMPOSIA

Study Section member, Oklahoma Center for the Advancement of Scientific Technology, Equipment Allocation Panel (1989)

Chair, Molecular Genetics Panel, Health Science Research Grants, Oklahoma Center for the Advancement of Science (1991-96)

Ad hoc member of the Molecular Biology (1991) and Developmental Biology (1994) Panels, American Cancer Society

Ad hoc reviewer of multiple grants to the National Science Foundation (Genetic Biology, Cellular and Physiology Panels), and to the March of Dimes Research Foundation

University of Georgia Research Foundation Biotechnology Grants Program (1988-89)

Consultant, Animal Sciences Division, Eli Lilly & Company (1987-93)

External Advisory Committee on Program Project grant, "Toxic Probes of Neuro-degenerative Disease," Center for Environmental and Occupational Toxicology, University of Oregon Health Sciences Center (1990-92)

Co-organizer with Larry Shinkets, Regional Conference of the Southeastern Society for Developmental Biology Conference (1993)

Director, Cell & Developmental Faculty Program, University of Georgia (1993-2000)

Ad hoc Review Committee for Program Projects, member, "Mechanisms of muscle aging: analysis and intervention," reverse site visit, National Institute on Aging, NIH (1995)

Ad hoc reviewer, Academic Research Initiation Grants Program, North Carolina Biotechnology Center (1997-99)

Chairman, Scientific Advisory Board of Avigenics, inc. (1996-present)

Member, Board of Directors, AviGenics, inc. (1996-98)

Ex officio Member, Board of Directors, AviGenics, inc. (1999-02)

Advisory Committee member, Applied Genetic Technology Resource (AGTEC), UGA (1997-2000)

Director, Avian Transgenesis Resource, University of Georgia (1997-2000)

Ad hoc reviewer, USDA, Growth and Differentiation panel, (1997-present)

Ad hoc reviewer, USDA National Research Initiative, Molecular Genetics, (1997-present)

Tertiary reviewer, Oklahoma Ctr. for the Advancement of Scientific Technol., (1999-00)

Member, Health Research and Applied Research panels, Oklahoma Ctr. for the Advancement of Scientific Technol., (2000 –2007))

Ad hoc reviewer, Science Council of British Columbia, Technology BC program (2000-present)

Chair, Avian Transgenesis, Int. Symposium on Transgenics in Agriculture, Beijing (2000)

Growth and Nutrition Panel Member, National Research Initiative, USDA (2001)

Organizer, Avian Transgenesis, Atlanta GA, funded by a \$5,000 grant from the USDA.

EDITORIAL SERVICE

Associate Editor, *Analytical Biochemistry* (7/1/89-2/28/96)

Executive Editor, *Analytical Biochemistry* (3/1/96 to present)

Ad hoc Reviewer for journals and textbooks:

<u>Journals</u>	<i>Analytical Biochemistry</i>	<i>J. Biological Chemistry</i>
	<i>Animal Genetics</i>	<i>J. Molecular Evolution</i>
	<i>BCM Evolutionary Biology</i>	<i>J. Molecular Biology</i>
	<i>Biotechnology Laboratory</i>	<i>Molecular & Cellular Biology</i>
	<i>Cancer Research</i>	<i>Nature Genetics</i>
	<i>Cell</i>	<i>Nature Biotechnology</i>

<i>Developmental Dynamics</i>	<i>Nucleic Acids Research</i>
<i>J. Cell Biology</i>	<i>Plant Cell</i>
<i>Gene</i>	<i>Plant Physiology</i>
<i>Genes and Development</i>	<i>Poultry Science</i>
<i>Growth, Dev. & Aging</i>	<i>Proc. National Academy of Sciences</i>
<i>J. Animal Science</i>	<i>Transgenic Research</i>

Textbooks

- Davis & Weller's *Gist of Genetics*
- Reid's *Creative Thinking Exercises for Genetics*
- Shotwell's *Genetics, Science & Technology*
- Snustad et al.'s *Principles of Genetics*
- Suzuki et al.'s *Introduction to Genetic Analysis*
- Klug & Cummings *Concepts of Genetics*
- Griffith's et al.'s *Modern Genetic Analysis*
- Hartwell et al.'s *Genetics: From Genes to Genomes*
- Brooker's *Genetics: Applications and Principles*
- Young's *Analytical Genomics*
- Russell's *iGenetics* (2nd ed.)
- Hartwell et al.'s *Genetics: From Genes to Genomes* (2nd ed.)

SYMPOSIA PRESENTATIONS

- 1970 Annual Meeting of the American Society of Microbiology (short talk).
- 1974 Gene Regulation in Mammals, The Jackson Laboratory, Bar Harbor, Maine (talk).
- 1976 Electrofocusing and Isotachopheresis Conference, Hamburg, Germany (talk).
- 1979 ICN-UCLA Symposium, Eukaryotic Gene Regulation, Keystone, Colorado (poster).
- 1980 Atlanta Genetics Society, University of Georgia, Athens, Georgia. (poster).
- 1981 First International Congress on Recombinant DNA, San Francisco, California (poster).
- 1982 Endocrine Society Meeting, GH3 Cell Subgroup, San Francisco, California (talk).
- 1983 FASEB Summer Research Conference, Somatic Cell Genetics, Saxton's River, Vermont (talk).
- 1984 FASEB Summer Research Conference, Somatic Cell Genetics, Saxton's River, Vermont (2 posters).
- 1985 6th Annual West Coast Chromosomes and Chromatin Meeting, Asilomar, California (talk).
- 1985 "GH Pituitary Cell Strains as Tools in Molecular and Cellular Biology," NATO International Workshop, Chantille, France (talk; session chair).
- 1986 Annual meeting of Genetics Society, San Francisco, California (2 posters). "Molecular Biology of the Nucleus," Pennsylvania State University Symposium, State College, Pennsylvania (poster).
- 1987 Annual meeting of the Genetics Society, San Francisco, California (poster).
- 1988 Annual conference of the American Meat Science Association, University of Wyoming, Laramie (plenary session talk).
- British Cell Biology Society symposium on "Differentiation: New Perspectives," Oxford University, England (poster).
- International Genetics Conference, Ontario, Canada (poster).
- 1989 UCLA Symposium on "Nucleic Acid Methylation," Frisco, Colorado (talk, poster).
- Cell Biology meeting, San Francisco, California (poster).
- CIBA Foundation workshop on DNA methylation, London, England (talk).
- 1990 UCLA Symposium on "Growth Factors and Differentiation", Steamboat Springs, Colorado (poster).
- Second New England BioLabs Workshop on Biological DNA Modification, Berlin, Germany (talk, poster).
- FASEB summer symposium on Gene Regulation, Copper Mountain, Colorado (poster).
- FASEB summer symposium on Genetics and Molecular Biology, Copper Mountain, Colorado (poster).
- 1991 UCLA Symposium on "Neuromuscular Development," Keystone, Colorado (poster).

- 1992 American Society of Animal Science Biennial Growth Symposium, Pittsburgh, Pennsylvania (plenary talk).
UCLA Symposium on "Growth and Differentiation Factors in Vertebrate Development," Keystone, Colorado (poster).
Jacques Monod Conference on "Early Steps in Development," Aussois, France (talk).
Gordon Research Conference on "Myogenesis," Tilton, NH (two posters).
- 1993 Southeastern Regional Developmental Biology Conference, University of Georgia (talk, two posters)
- 1994 UCLA Keystone Symposium, "Muscle Development", Snowbird, Utah (two posters)
- 1997 Animal Science Conference, "Transgenic Animals in Agriculture", Athens, Georgia (session talk)
- 1998 Plant & Animal Genomes Conference, San Diego, CA (poster)
UCLA Symposium on Vertebrate Development, Steamboat Springs, CO (poster)
Genetically Engineering & Cloning Animals: Science, Society & Industry Symposium, Park City/Deer Valley, UT (poster)
- 1999 Plant & Animal Genomes Conference, Poultry Genome Workshop, San Diego CA (talk)
Agricultural Genomics: New Technologies, Functions & Advances, Chairman of Transgenics Track, San Diego, CA (talk with Mike McDonell)
Transgenic Animal Research Conference, Tahoe City, CA (talk)
Protein Production Conference, Washington DC (poster)
- 2000 Joint Meeting of the American Dairy Science Association and the American Society of Animal Science, Baltimore MD (talk, with Dr. Mike McDonell)
International Conference on Transgenesis in Agriculture, Beijing, PRC (Chair, Avian Transgenesis, session talk)
- 2001 Transgenic Animals in Agriculture, Tahoe City, CA (poster)
- 2002 Sigma Xi Society, Guest Speaker, Athens, GA
Poultry Science Association Ancillary Meeting on Biotechnology (session talk, with Glenn Monastersky)
Keynote speaker (one of two), Dedication of the Animal Biotechnology Building, University of Maryland and USDA.
- 2003 Plant and Animal Genome Conference, San Diego, CA (poster)
Poultry Workshop, Plant and Animal Genome Conference, San Diego, CA (session talk with Thomas Wicker).
- 2004 Plant and Animal Genome Conference, Poultry Workshop, San Diego, CA (session talk)
- 2005 Plant and Animal Genome Conference, Reduced-Representation Workshop, San Diego, CA (session talk).
- 2006 Next Generation of Protein Therapeutics, Basel, Switzerland (session talk).

RESEARCH SEMINARS (since postdoctoral)

- 1976 Department of Pharmacology, State University of New York, Stony Brook, New York.
Imperial Cancer Research Fund, Lincoln's Inn Fields, London.
Basel Institute for Immunology, Basel, Switzerland.
University of Geneva Medical School, Geneva, Switzerland.
- 1977 Department of Biochemistry and Biophysics, University of California, San Francisco, CA
Metabolic Research Unit, School of Medicine, University of California, San Francisco, CA
Biology Department, University of Indiana, Bloomington, Indiana.
Department of Endocrinology, School of Medicine, University of Texas, Dallas, Texas.
- 1978 Division of Biological Sciences, University of Missouri, Columbia, Missouri.
- 1979 Department of Biochemistry, Brandeis University, Waltham, Massachusetts.
Department of Biochemistry, University of Georgia, Athens, Georgia.
Department of Biochemistry, University of Missouri, Columbia, Missouri.
Medical Research Center, Prince Henry's Hospital, Melbourne, Australia.
- 1982 Department of Molecular & Population Genetics, University of Georgia, Athens, Georgia
Medical Research Center, Prince Henry's Hospital, Melbourne, Australia.

- Walter and Eliza Hall Institute, Royal Melbourne Hospital, Melbourne, Australia.
- 1983 Department of Genetics, North Carolina State University, Raleigh, North Carolina.
Molecular Genetics Section, Pfizer Corporation, Groton, Connecticut.
Department of Biology, Emory University, Atlanta, Georgia.
Endocrinology & Metabolic Disease Section, Medical College of Georgia, Augusta, Georgia.
- 1984 Department of Endocrinology, Medical College of Georgia, Augusta, Georgia.
Department of Cell Biology, Upjohn Company, Kalamazoo, Michigan.
Department of Biochemistry & Biophysics, University of California, San Francisco, California.
Metabolic Research Unit, Division of Endocrinology, Department of Medicine,
University of California, San Francisco, California.
- 1985 Division of Cancer Research, Upjohn Company, Kalamazoo, Michigan.
CSIRO Division of Molecular Biology, Sydney, Australia.
Department of Genetics, Australia National University, Canberra City.
The Cancer Institute, Peter MacCallum Hospital, Melbourne, Australia.
Medical Research Center, Prince Henry's Hospital, Melbourne, Australia.
Department of Genetics and Human Variation, La Trobe University, Bundoora, Australia.
Genetics Department Retreat, University of Georgia, Sapelo Island, Georgia.
Biotechnology Seminar Series, School of Agriculture, University of Georgia, Athens, Georgia.
- 1986 Department of Pharmacy, Rutgers Medical School, Rutgers University.
- 1987 Division of Animal Science, Eli Lilly & Co., Greenfield Labs, Greenfield, Indiana.
Department of Genetics, University of Georgia, Athens, Georgia.
Metabolic Research Unit, Department of Medicine, University of California, San Francisco, California.
Cetus Corporation, Emeryville, California.
- 1988 Genetics Department Retreat, University of Georgia, Unicoi, Georgia.
- 1989 Animal Science Division, Greenfield Labs, Eli Lilly & Company, Greenfield, Indiana.
Department of Biological Chemistry, University of Illinois, Chicago, Illinois.
Department of Endocrinology, University of Colorado Health Science Center, Denver, Colorado.
Centre for Molecular Biology and Biotechnology, University of Queensland, St. Lucia, Queensland,
Australia.
- 1990 Lilly Research Labs, Animal Science Division, Greenfield, Indiana.
Department of Physiology and Pharmacology, School of Veterinary Medicine, University of Georgia,
Athens, Georgia.
Agricultural Education Department, University of Georgia, Athens, Georgia.
Department of Biochemistry and Molecular Biology, University of Oklahoma Health Science Center,
Oklahoma City, Oklahoma.
- 1991 Lilly Research Labs, Animal Science Division, Greenfield, Indiana.
Baker Institute for Medical Research, Melbourne, Australia.
- 1992 Walter and Eliza Hall Institute for Medical Research, Melbourne, Australia.
Genetics Department, University of Georgia, Athens, Georgia.
Poultry Science Department, University of Georgia, Athens, Georgia.
Department of Pharmacology, University of Georgia, Athens, Georgia.
- 1993 Lilly Research Lab, Animal Science Division, Greenfield, Indiana
- 1994 Genetics Department, Athens, Georgia
Institute of Child Nutrition & Development, Baylor University, Houston, Texas
- 1995 Arbor Acres Farm, Hartford, Connecticut
Goldkist Corporation, Atlanta, Georgia
- 1996 Crystal Farms, inc. Gainesville, Georgia
J & S Farms, Gainesville, Georgia
Technology Venture Alliance, inc., Atlanta, Georgia
Asset Management, inc., Menlo Park, California
- 1997 Roche Vitamins and Fine Chemicals Division, Basel, Switzerland
S.E. Animal Care Society's symposium on transgenic animals, Athens, GA.
Recombination Biocatalysis, Inc., San Diego, CA.
Department of Pharmacy, University of Georgia, Athens, GA

	Schering-Plough, Inc. Biotechnology Group, Newark, NJ
	MetaMorphix, Inc., Molecular Biology Division, Baltimore, MD
	Noro-Moseley Partners, Atlanta, GA
1998	Department of Genetics, University of Georgia, Athens
	Cordova Capital, Atlanta
	Department of Animal and Dairy Science, University of Georgia, Athens
	Oakwood Laboratory, Cleveland
	Department of Animal Science & Technology, Seoul National University, Suweon, South Korea
1999	Department of Poultry Diagnostic & Research Center, University of Georgia, Athens
	Michigan State University, Department of Microbiology & the Avian Disease and Oncology Lab, USDA, East Lansing.
	Department of Poultry Science, University of Georgia, Athens
2000	Department of Animal Science & Technology, Seoul National University, Suweon, S. Korea
	Life Sciences Division, Mitsubishi Corporation, Tokyo, Japan
2002	Clark Atlanta University, Department of Biology, Atlanta, GA
2004	Genetics Department Retreat, University of Georgia, Athens

PUBLICATIONS (peer-reviewed)

1. Ivarie, R.D., and Pene, J.J. (1970). Association of the *Bacillus subtilis* chromosome with the cell membrane: Resolution of free and bound deoxyribonucleic acid on Renografin gradients. *J. Bacteriol.* 104, 839-850.
2. Ivarie, R.D. (1972). Association of bacterial and viral deoxyribonucleic acid with the cell membrane. Ph.D. Dissertation, University of Colorado.
3. Ivarie, R.D., and Pene J.J. (1973). Association of many regions of the *Bacillus subtilis* chromosome with the cell membrane. *J. Bacteriol.* 114, 571-576.
4. Ivarie, R.D., and Pene, J.J. (1973). DNA replication in bacteriophage f29: The requirement of a viral-specific product for association of phage DNA with the cell membrane of *Bacillus amyloliquefaciens*. *Virology* 52, 351-362.
5. Steinberg, R.S., Scott, W.A., Levinson, B.B., Ivarie, R.D., and Tomkins, G.M. (1974). Glucocorticoid induction of tyrosine aminotransferase, in *Regulation of Gene Expression in Eukaryotic Cells* (25). Washington, DC: U.S. Government Printing Off., Fogarty International Center Proc.
6. Ivarie, R.D., Fan, W., and Tomkins, G.M. (1975). Analysis of the induction and deinduction of tyrosine aminotransferase by glucocorticoids in anucleate HTC cells. *J. Cell. Physiol.* 85(2), 357-364.
7. Fan, W., Ivarie, R.D., and Levinson, B.B. (1977). Requirement of the nucleus for the intracellular degradation of tyrosine aminotransferase in HTC cells. *J. Biol. Chem.* 252, 7834-7841.
8. Ivarie, R.D., and O'Farrell, P.H. (1978). The glucocorticoid domain: The steroid-mediated induction of specific proteins in rat hepatoma cells. *Cell* 13, 45-51.
9. Seeburg, P.H., Martial, J.A., Shine, J., Ivarie, R.D., Morris, J.A., Ullrich, A., Baxter, J.D., and Goodman, H.M. (1978). Synthesis of growth hormone by bacteria. *Nature* 276, 795-798.
10. Rubenstein, P.R., and Ivarie, R.D. (1979). Isolation of two different molecular weight polypeptides co-purifying with rat liver tyrosine aminotransferase. *Arch. Biochem. Biophys.* 194, 299-311.
11. Ivarie, R.D., and Jones, P.O. (1979). A rapid assay for specific protein synthesis in cells and in cell-free translations: Use of *Staphylococcus aureus* I as an adsorbent for immune complexes, *Anal. Biochem.* 97, 24-35.
12. Ivarie, R.D., Baxter, J.D., and Morris, J.A. (1981). Interaction of thyroid and glucocorticoid hormones in rat pituitary tumor cells: Specificity and diversity of the responses analyzed by two-dimensional gel electrophoresis. *J. Biol. Chem.* 256, 4520-4528.
13. Ivarie, R.D., Morris, J.A., and Martial, J.A. (1982). Prolactin-deficient variants of GH3 rat pituitary tumor cells: Linked expression of prolactin and another hormonally responsive protein in GH3 cells. *Mol. Cell Biol.* 2, 179-189.

14. Ivarie, R.D., and Morris, J.A. (1982). Induction of prolactin-deficient variants of GH₃ rat pituitary tumor cells by ethyl methanesulfonate: Reversion by the DNA methylation inhibitor, 5-azacytidine. *Proc. Natl. Acad. Sci., USA* **79**, 2967-2970.
15. McClelland, M., and Ivarie, R.D. (1982). Asymmetrical distribution of CpG in an "average" mammalian gene. *Nucleic Acids Res.* **10**, 7865-7877.
16. Ivarie, R.D., and Morris, J.A. (1983). Phenotypic switching in GH₃ rat pituitary tumor cells: Linked expression of growth hormone and another hormonally responsive protein. *DNA* **2**, 113-120.
17. Ivarie, R.D., Schacter, B.S., and O'Farrell, P.H. (1983). The level of expression of the rat growth hormone gene in liver tumor cells is at least eight orders of magnitude less than in anterior pituitary. *Mol. Cell. Biol.* **3**, 1460-1467.
18. Farrance, I.K., and Ivarie, R.D. (1985). Ethylation of poly(dC-dG)-poly(dC-dG) by ethyl methanesulfonate stimulates the activity of mammalian DNA methyltransferase *in vitro*. *Proc. Natl. Acad. Sci., USA* **82**, 1045-1049.
19. Ivarie, R.D., and Morris, J.A. (1986). Activation of a nonexpressed HPRT allele in mutant H23 HeLa cells by agents that inhibit DNA methylation. *Mol. Cell. Biol.* **6**, 97-104.
20. Morris, J.A., Kushner, S.R., and Ivarie, R.D. (1986). The simple repeat poly(dT-dG)-poly(dC-dA) common to eukaryotes is absent from eu- and archaebacteria and rare in protozoans. *Mol. Biol. Evol.* **4**, 343-355.
21. McFarlane, D., Farrance, I.K., Hall, I., Morris, J.A., & Ivarie, R.D. (1986). The rat prolactin gene contains at least six poly(dT-dG)-poly(dC-dA) repeats. *Nucleic Acids Res.* **14**, 7805.
22. Phillips, G.J., Arnold, J., and Ivarie, R.D. (1987). Mono-through hexanucleotide composition of the E. coli genome: A Markov chain analysis. *Nucleic Acids Res.* **14**, 2611-26.
23. Phillips, G.J., Arnold, J., and Ivarie, R.D. (1987). The effect of codon usage on the oligonucleotide composition of the E. coli genome and identification of over- and underrepresented sequences by Markov chain analysis. *Nucleic Acids Res.* **14**, 2627-38.
24. Davis, R.E., Morris, J.A., and Ivarie, R.D. (1987). The polypeptide P16 is a carboxyl terminal cleavage product of rat growth hormone in anterior pituitary and GH₃ pituitary tumor cells. *Mol. Endocrinol.* **1**, 102-108.
25. Ivarie, R.D. (1987). Thymine methyls and DNA-protein interactions. *Nucleic Acid Res.* **15**, 9975-83.
26. Arnold, J., Cuticchia, A.J., Newsome, D.A., Jennings, W.W., and Ivarie, R.D. (1988). Mono- through hexanucleotide composition of the sense strand of yeast DNA: A Markov chain analysis. *Nucleic Acids Res.* **16**, 7145-57.
27. Farrance, I.K., Eadie, J. S., and Ivarie, R.D. (1989). Improved chemistry for oligodeoxyribonucleotide synthesis substantially improves restriction enzyme cleavage of a synthetic 35mer. *Nucleic Acids Res.* **17**, 1231-45.
28. Farrance, I.K. and Ivarie, R.D. (1989). Synthesis of N7-ethyldeoxyguanosine-5'-triphosphate and site-specific placement of N7-ethylguanine in a synthetic 35mer. *Anal. Biochem.* **179**, 60-65.
29. Clark, T.G., Morris, J.A., Akamatsu, M., McGraw, R.A., and Ivarie, R.D. (1990). A bovine cDNA homolog to the human myogenic determination factor *myf-5*: Sequence conservation and 3' processing of transcripts. *Nucleic Acids Research* **18**, 3147-53.
30. Arnold, T.E., Farrance, I.K., Hall, I.S., Morris, J.A., and Ivarie, R.D. (1991). Prolactin-deficient GH₃ rat pituitary tumor cells express prolactin transcription factor pit-1 and reduced levels of primary PRL transcripts that harbor normal 5' and 3' termini. *DNA Cell Bio.* **10**, 105-112.
31. Cuticchia, A.J., Ivarie, R. and Arnold, J. (1992). The application of Markov chain analysis to oligonucleotide frequency predictions and physical mapping of *Drosophila melanogaster*. *Nucleic Acids Res.* **20**, 3651-3657.
32. Coutinho, L.L., Morris, J. and Ivarie, R. (1992). Whole mount *in situ* detection of low abundance transcripts (*qmf1*) and protein (MHC) in quail embryos using light and confocal laser scanning microscopy. *Biotech.* **13**, 722-724.
33. Barth, J., Worrell, R.A., 185-919Crawford, J.M., Morris, J. and Ivarie, R. (1993). Isolation of the bovine *myf5* gene and characterization of its multiple transcripts. *Gene*, **127**, 185-191.
34. Coutinho, L.L., Morris, J., Marks, H.A. and Ivarie, R. (1993). Delayed somite formation is accompanied by a delay in the expression of myogenic regulatory factors and myosin heavy chain in a quail line exhibiting myofiber hyperplasia. *Development*, **117**, 563-569.
35. Santerre, R.F., Bales, K.R., Janney, M.J., Fisher, L.F., Bailey, C.S., Morris, J., Ivarie, R.D., and Smith, C.K. (1993). Expression of bovine *myf5* produces ectopic skeletal muscle formation in transgenic mice. *Mol. Cell. Bio.*, **13**, 6044-6051.

36. Arnold, T.E., Worrell, R.A., Barth, J., Morris, J. and Ivarie, R. (1994). Dexamethasone-mediated induction of MMTV-*myf5* in DD3 myoblasts increases endogenous *myogenin* expression but does not transactivate *myf5*, *Exptl. Cell Res.*, **212**, 321-328.
37. Barth, J. L. and Ivarie, R. (1994) Polyvinyl alcohol enhances detection of low abundance transcripts in early stage quail embryos in a nonradioactive whole mount *in situ* hybridization technique. *Biotechniques*, **17**, 324-327.
38. Barth, J.L. and Ivarie, R. (1994) Polyvinyl alcohol enhances the BCIP/NBT alkaline phosphatase color reaction in a nonradioactive whole mount *in situ* hybridization procedure. *Biochemica*, **3**, 12-13.
39. Barth, J.L., Morris, J.A. and Ivarie, R. (1997) An oct-like binding factor regulates *Myf-5* expression in primary avian cells, *Exptl. Cell Res.*, **238**, 430-438.
40. Speksnijder, G. and Ivarie, R. (2000) A modified method of shell windowing for producing somatic or germline chimeras in fertilized chicken eggs, *J. Poultry Sci.*, **79**, 1430-1433.
41. Harvey, A.J., Speksnijder, G., Baugh, L.R., Morris, J.A. and Ivarie, R. (2002) Consistent production of transgenic chickens using replication-deficient retroviral vectors and high-through screening procedures, *Poultry Sci.* **81**, 202-212.
42. Harvey, A.J., Speksnijder, G., Baugh, L. and Ivarie, R. (2002) Expression of exogenous protein in the egg white of transgenic chickens, *Nature Biotechnol.*, **19**, 396-399.
43. Mott, I. and Ivarie, R. (2002) Expression of myostatin is not altered in lines of poultry exhibiting myofiber hyper- and hypoplasia, *Poultry Sci.*, **81**, 799-804.
44. Ivarie, R. (2003) Avian transgenesis: progress toward the promise, *Trends in Biotechnol.*, **21**, 14-19.
45. Rapp, J., Hu, W., Harvey, A.J. and Ivarie, R. (2003) Transgenic hens producing biologically active interferon- α 2b in egg whites stably through three generations, *Transgenic Res.*, **12**, 596-575...
46. Ivarie, R. and A.J. Harvey (2003) Validation of the hen as a bioreactor for the production of exogenous proteins in egg white, *Poult. Sci.*, **82**, 927-930.
47. Mott, I. and Ivarie, R. (2004) cDNA array analysis of Japanese quail lines divergently selected for four-week body weight, *Poult. Sci.* **83**, 1524-1529.
48. Andacht, T. and Ivarie, R. (2004) A rapid and improved method for windowing eggs accessing the stage X chicken embryo, *Mol. Reprod. Dev.* **69**, 31-34.
49. Wicker, T., Robertson, J.S., Schulze, S.R., Feltus, F.A., Magrini, V., Morrison, J.A., Mardis, E.K. Wilson, R.K., Peterson D.G., Paterson, A.H., and Ivarie, R. (2005) Repetitive landscape of the chicken genome, *Genome Res.* in press (published online, July 2004).
50. Chicken Genome Consortium (1 of 175 coauthors). (2004) Sequence and comparative analysis of the chicken genome provide unique perspectives on vertebrate evolution, *Nature* **432**, 695-715.
51. Wicker, T., Robertson, J.S., Feltus, F.A., Schulze, S.R., Ivarie, R., and Paterson, A.H. (2006) Rapidly-associating DNA takes on diverse secondary structures with many biological functions, submitted for publ.
52. Ivarie, R. (2006) Competitive hen bioreactors on the horizon. *Trends in Biotechnology* **24**, 99-101.

TEXTBOOKS AND INVITED PAPERS

1. Ivarie, R.D., Gelfand, D.H., Jones, P.P., O'Farrell, P.A., Polisky, B.A., Steinberg, R.A., and O'Farrell, P.H. (1977). Biological applications of two-dimensional gel electrophoresis, in B.J. Radola & D. Graesslin (Eds.), *Electrofocusing and Isotachopheresis* (Berlin, NY: Walter de Gruyter), pp. 369-384.
2. Baxter, J.D., and Ivarie, R.D. (1978). Regulation of gene expression by glucocorticoid hormones: Studies of receptors and responses in cultured cells, in B. O'Malley and L. Birnbaumer (Eds.), *Hormone Receptors*, (New York, Academic Press), **2** 252-296.
3. Ivarie, R.D., and O'Farrell, P.H. (1978). The glucocorticoid domain: The steroid-mediated induction of specific proteins in rat hepatoma cells. *Cell* **13**, 45-51.
4. Yamamoto, K.R., Ivarie, R.D., Ring, J., Ringold, G.M., and Stallcup, M.R. (1978). Integrated mammary mouse virus genes: Transcriptional regulation by glucocorticoids and specific effects on host gene expression, in G. Litwack (Ed.), *Biochemical Actions of Hormones* **5** (New York: Academic Press), 373-395.
5. O'Farrell, P.H., and Ivarie, R.D. (1979). The glucocorticoid domain of response: Measurement of pleiotropic cellular responses by two-dimensional gel electrophoresis, in J.D. Baxter and G.G. Rousseau (Eds.), *Glucocorticoid Hormone Action* (Heidelberg: Springer-Verlag), 189-201.

6. Steinberg, R.S., and Ivarie, R.D. (1979). Post-transcriptional regulation of glucocorticoid-regulated functions, in J.D. Baxter and G.G. Rousseau (Eds.), *Glucocorticoid Hormone Action* (Heidelberg: Springer-Verlag), 291-304.
7. Baxter, J.D., Eberhardt, N.L., Apriletti, J.W., Johnson, L.K., Ivarie, R.D., Schachter, B., Morris, J.A., Seeburg, P.H., Goodman, H.M., Lathan, K.R., and Polansky, J.R. (1979). Thyroid hormone receptors and responses. *Rec. Prog. Hormone Res.* 35, 97-153.
8. Baxter, J.D., Seeburg, P.H., Shine, J., Martial, J.A., Ivarie, R.D., Johnson, L.K., Fiddes, J.C., and Goodman, H.M. (1979). Structure of growth hormone gene sequences and their expression in bacteria and in cultured cells, in G. Sato and R. Ross (Eds.), *Hormones and Cell Culture* 6 (Cold Spring Harbor: Cold Spring Harbor Laboratory), 317-337.
9. Ivarie, R.D., Morris, J.A., and Eberhardt, N. L. (1980). Hormonal domains of response: Actions of glucocorticoid and thyroid hormones in regulating pleiotropic responses in cultured cells. *Rec. Prog. Hormone Res.* 36, 195-239.
10. Ivarie, R.D., Morris, J.A., and Clark, T.G. (1988). Gene regulation in muscle development and control of myogenic lineage by determination genes. *Proc., 41st Reciprocal Meat Conference of the Amer. Meat Sci. Assoc.*, 61-68.
11. Farrance, I.K., Arnold, T.E., Hall, I.S., Morris, J.A., and Ivarie, R.D. (1990) On the mechanism underlying inactivation of prolactin gene transcription in GH₃ rat pituitary tumor cells, in G. Clawson, D. Willis, A. Weissbach and P. Jones (Eds.), *Nucleic Acid Methylation* 128 (UCLA Symposia on Molecular and Cell Biology, New Series), 229-245.
12. Ivarie, R. (1993). Role of myogenic regulatory factors in skeletal muscle growth and differentiation. *J. Anim. Sci.* 71, 23-32.
13. Ivarie, R. (1997) *Genetics Instructor Manual and Question Test Bank*, 1st ed., John Wiley & Sons.
14. Ivarie, R. (1999) *Genetics Instructor Manual and Question Test Bank*, 2nd ed. John Wiley & Sons.
15. Ivarie, R. (2005) *Genetics Instructor Manual and Question Test Bank*, 3rd ed. John Wiley & Sons.

ABSTRACTS (published)

1. Ivarie, R.D., and Pene, J.J. (1970). Isolation of membrane-bound in *Bacillus subtilis* by sedimentation on renografin density gradients. *Bacteriol. Proc.*, 54.
2. O'Farrell, P.H., and Ivarie, R.D. (1979). Extinction of gene expression by differentiation. *J. Supramolec. Struct* (suppl. 3), 147.
3. Ivarie, R.D., and Morris, J.A. (1981). Prolactin-deficient variants of GH₃ rat pituitary tumor cells. *DNA* 1, 80.
4. Ivarie, R.D., and Morris, J.A. (1984). Activation of a silent HPRT allele in HeLa cells by 5-azacytidine. *J. Supramolec. Struct.* (suppl. 8B), 35.
5. Ivarie, R.D., Davis, R., and Morris, J.A. (1985). Multihormonal control of gene expression and phenotypic switching in a clonal line of GH₃ rat pituitary tumor cells. NATO Adv. Res. Workshop on "GH Pituitary Cell Strains as Tools in Molec. & Cell. Biol.", 11.
6. Farrance, I.K., and Ivarie, R.D. (1986). Alkylation of poly(dC-dG)·poly(dC-dG) stimulates the activity of mammalian DNA methyltransferase. *Genetics* 110, 590.
7. Farrance, I.K., and Ivarie, R.D. (1986). EMS-modified poly(dC-dG)·poly(dC-dG) stimulates DNA methyltransferase activity. Pennsylvania State University Symposium on "Molecular Biology of the Nucleus."
8. Farrance, I.K., and Ivarie, R.D. (1987). Site-specific placement of N7-ethylguanine in DNA. *Genetics* 116 (pt. 2).
9. Ivarie, R., Phillips, G.J., and Arnold, J. (1987). A 3rd and 4th order Markov chain rule most accurately predicts oligonucleotide frequencies in DNA sequences. *Genetics*, 110 (pt. 2).
10. Arnold, J., Cuticchia, A.J., Newsome, D.A., Jennings, W.W., and Ivarie, R.D. (1988). Mono- through hexanucleotide composition of the sense strand of yeast DNA: A Markov chain analysis. *Genetics*, in press.
11. Farrance, I.K., Hall, I.S., Morris, J.A., and Ivarie, R.D. (1988). Prolactin-deficient GH₃ rat pituitary tumor cells express reduced levels of primary PRL transcripts that are correctly processed to mature messages. "Differentiation: New Perspectives," British Cell Biology meeting.
12. Farrance, I.K., Hall, I.S., Morris, J.A., Arnold, T.E., and Ivarie, R.D. (1989). A prolactin-deficient variant of GH₃ rat pituitary tumor cells contains substantially reduced levels of primary transcripts of the prolactin gene that

are correctly processed to mature messages. Joint meeting of the American Society for Biochemistry and Molecular Biology and for Cell Biology.

13. Arnold, T.E., and Ivarie, R.D. (1989). Prolactin-deficient GH₃ cells are fully competent to initiate transcription from the prolactin gene promoter. UCLA Symposium on Nucleic Acid Methylation, *J. Cell. Biochem.*

14. Clark, T.G., Akamatsu, M., Morris, J.A., McGraw, R., and Ivarie, R.D. (1990). A bovine cDNA homolog to the human myogenic determination factor *myf-5*: Sequence conservation and 3' processing of transcripts. UCLA Symposium on Growth Factors and Differentiation, *J. Cell. Biochem.*

15. Arnold, T.E., Barth, J.L., Worrell, R.A., Morris, J.A., and Ivarie, R.D. (1991). Gene structure and functional analysis of the myogenic factor *bmyf*, a bovine homolog of *myf-5*. *J. Cell. Biochem.* (suppl. 15C), 20.

16. Coutinho, L.C., Morris, J., Marks, H.L. and Ivarie, R. (1992) Delay of early somite development and myosin heavy chain expression (MHC) in quail (*Coturnix coturnix japonica*) selected for high growth rate. *J. Anim. Sci.* **70**, 214.

17. Worrell, R.A., Arnold, T.E., Morris, J. and Ivarie, R. (1992) The bovine *myf5* gene can activate all of the endogenous myogenic factor gene except the endogenous *myf5* gene in 10T1/2-derived myoblasts. *Mol. Cell Bio.* **3**, 199.

18. Ivarie, R., Coutinho, L.L., Morris, J. and Marks, H.L. (1992) Delayed somite formation and muscle-specific gene activation in a genetic line of Japanese quail with extensive muscle hyperplasia. *Mol. Cell Bio.* **3**, 108.

19. Ivarie, R., Shimkets, R. and Worrell, R.A. (1994) Cell type-specific expression from the bovine *myf5* promoter. *J. Cell. Biochem.* (suppl D.) p. 498.

20. Barth, J.L., Morris, J. Marks, H. and Ivarie, R. (1994) Rates of somite formation and muscle-specific gene expression in growth-selected lines of Japanese quail. *J. Cell. Biochem.* (Suppl. D) p. 492.

21. Speksnijder, G.L., Liu, G., Baugh, L, Harvey, A.J. and Ivarie, R. (1998) Novel windowing method yields a high number of somatic and germline transgenic chimeras in the chicken, Plant and Animal Genomes Conference.

22. Speksnijder, G.L., Liu, G., Baugh, L, Harvey, A.J. and Ivarie, R. (1998) Novel windowing method yields a high number of somatic and germline transgenic chimeras in the chicken, J. Cell. Biochem. Keystone Conference on Vertebrate Development.

23. Ivarie, R., Speksnijder, G.L., Baugh, L. and Harvey, A.J. (1999) Validating the hen as a bioreactor for the production of a biologically active foreign protein in egg white, *Transgenic Research*, in press.

24. Rapp, J.C., Harvey, A.J., speksnijder, G., Hu, w., Caplan, B. and Ivarie R.D. (2001) Production of human interferon α -2b in the egg white of transgenic hens, *Transgenic Res.* **11**, 90.

25. Ivarie, R., Wicker, T., Robinson, J., Feltus, A., Magrini, V., Mardis, E., and Paterson, A. (2005) "The repetitive DNA landscape of the chicken genome," Plant and Animal Genome Abstracts, W3115).